Merck says long-term cholesterol drug study met primary endpoint

(Reuters) - Merck & Co said on Monday that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol, had met its primary endpoint.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cholesterol | Health | Merck | Study | Vytorin | Zetia